eMedicine Specialties > Radiology > Genitourinary

Prostate Carcinoma: Follow-up

Author: Richard Clements, MBBCh, Consultant, Department of Clinical Radiology, Royal Gwent Hospital, South Wales
Contributor Information and Disclosures

Updated: Apr 18, 2007

Intervention

Patient education

For excellent patient education resources, visit eMedicine's Prostate Health Center and Cancer and Tumors Center. Also, see eMedicine's patient education article, Prostate Cancer.

Medicolegal Pitfalls

  • Biopsy must be performed with prophylactic antibiotic coverage because deaths have been reported when such antibiotic coverage has not been used. Many antibiotic regimens are in use. It is the author's current practice to use both a quinolone antibiotic and specific prophylaxis against anaerobic bacteria.
 


More on Prostate Carcinoma

Overview: Prostate Carcinoma
Imaging: Prostate Carcinoma
Follow-up: Prostate Carcinoma
Multimedia: Prostate Carcinoma
References
[ CLOSE WINDOW ]

References

  1. Noguchi M, Stamey TA, Neal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol. Jun 2000;163(6):1751-5.

  2. Sobin LH, Wittekind CL, eds. TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley & Sons;2002.

  3. Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J Clin. Mar-Apr 2006;56(2):106-30.

  4. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. Dec 1988;12(12):897-906. [Medline].

  5. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. Aug 18 1993;270(7):860-4. [Medline].

  6. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. Nov 1993;13;342(888):1209-10.

  7. Morton MS, Turkes A, Denis L, Griffiths K. Can dietary factors influence prostatic disease?. BJU Int. Sep 1999;84(5):549-54.

  8. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. Jun 19 2003;348(25):2491-9. [Medline].

  9. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. Mar 2001;7(1):27-37.

  10. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. Mar 1992;147(3 Pt 2):815-6. [Medline].

  11. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. May 20 1998;279(19):1542-7. [Medline].

  12. Clements R. Contemporary ultrasound guided biopsy in the diagnosis of prostate cancer. Imaging. 2001;13:18-26.

  13. Clements R. Prostate specific antigen: an opinion on its value to the radiologist. Eur Radiol. 1999;9(3):529-35. [Medline].

  14. Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol. Sep 1998;160(3 Pt 1):794-6. [Medline].

  15. Even-Sapir E, Metser U, Mishani E. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. Feb 2006;47(2):287-297.

  16. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced us for detection. Radiology. Apr 2001;219(1):219-25. [Medline].

  17. Hata N, Jinzaki M, Kacher D, et al. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology. Jul 2001;220(1):263-8. [Medline].

  18. Huch Boni RA, Boner JA, Debatin JF, et al. Optimization of prostate carcinoma staging: comparison of imaging and clinical methods. Clin Radiol. Sep 1995;50(9):593-600. [Medline].

  19. Kirby R, Christmas T, Brawer MK. Prostate Cancer. 2nd ed. St Louis: Mosby-Year Book;2001.

  20. Lavoipierre AM, Snow RM, Frydenberg M, et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol. Jul 1998;171(1):205-10. [Medline].

  21. Lawrentschuk N, Davis ID, Bolton DM. Positron emission tomography and molecular imaging of the prostate: an update. BJU Int. May 2006;97(5):923-31.

  22. Mettlin C, Chesley AE, Murphy GP, et al. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate. May 15 1999;39(3):153-8. [Medline].

  23. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol. Feb 2000;55(2):99-109. [Medline].

  24. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. May 14 1997;277(18):1445-51. [Medline].

  25. Presti JC Jr, Hricak H, Narayan PA, et al. Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol. Jan 1996;166(1):103-8. [Medline].

  26. Reske SN, Blumstein NM, Neumaier B. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. Aug 2006;47(8):1249-54.

  27. Rifkin MD. Ultrasound of the Prostate. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins;1996.

  28. Sandblom G, Sörensen J, Lundin N. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. May 2006;67(5):996-1000.

  29. Siegelman ES. Magnetic resonance imaging of the prostate. Semin Roentgenol. Oct 1999;34(4):295-312. [Medline].

  30. Terris MK. The appearance of adenoid cystic carcinoma of the prostate on transrectal ultrasonography. BJU Int. May 1999;83(7):875-6.

  31. Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol. Apr 1998;159(4):1251-9. [Medline].

  32. Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. Jun 1 2006;24(16):2513-9.

  33. Whitmore WF Jr. Localised prostatic cancer: management and detection issues. Lancet. May 21 1994;343(8908):1263-7. [Medline].

  34. Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. Feb 2005;184(2):676-80.

  35. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. Nov 1999;213(2):481-8. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

prostate carcinoma, prostatic cancer, prostatic carcinoma, prostatic adenocarcinoma, prostatic intraepithelial neoplasia, PIN, prostate-specific antigen, PSA, digital rectal examination, DRE, comedocarcinoma

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Richard Clements, MBBCh, Consultant, Department of Clinical Radiology, Royal Gwent Hospital, South Wales
Richard Clements, MBBCh is a member of the following medical societies: British Medical Association, Royal College of Radiologists, and Royal College of Surgeons of England
Disclosure: Nothing to disclose.

Medical Editor

John L Haddad, MD, Clinical Associate Professor, Department of Radiology, Weill Medical College of Cornell University; Director of Body MRI, Department of Radiology, Methodist Hospital in Houston
John L Haddad, MD is a member of the following medical societies: American College of Radiology, American Medical Association, and Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.

Managing Editor

Bruno D Fornage, MD, Professor of Radiology and Surgical Oncology, Department of Diagnostic Radiology, Division of Diagnostic Imaging and Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Disclosure: Nothing to disclose.

CME Editor

Robert M Krasny, MD, Consulting Staff, Department of Radiology, The Angeles Clinic and Research Institute
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.

Chief Editor

Eugene C Lin, MD, Consulting Staff, Department of Radiology, Virginia Mason Medical Center
Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, and Society of Nuclear Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.